ライフサイエンスコーパス: coinfected

1 ed by the HCV-monoinfected (19%) and HIV/HCV-coinfected (11%) (P = 0.003 across groups).

2 cohol consumption at enrollment (701 HIV/HCV-coinfected; 1410 HIV-monoinfected; 296 HCV-monoinfected;

3 ide conjugate vaccine, and then sequentially coinfected 5 weeks later with PR8 influenza virus and A6

4 ted a cross-sectional study among 50 HIV/HCV-coinfected, 51 HCV-monoinfected, and 50 HIV-monoinfected

5 in initiators vs nonusers among 7686 HIV/HCV-coinfected, 8155 HCV-monoinfected, 17739 HIV-monoinfecte

6 observational cohort study included HIV/HCV-coinfected adults with genotype 1 HCV who initiated trea

7 Of 118 participants, 7 were coinfected and 10 acquired superinfection.

8 Contrary to expectations, HIV/HCV-coinfected and HCV-monoinfected adults had significantly

9 HIV/HCV-coinfected and HIV-monoinfected women had higher median

10 In HIV/HCV-coinfected and HIV-monoinfected women, higher liver stif

11 Coinfected animals displayed higher levels of infection

12 lavage fluid were similar between mono- and coinfected animals through 24 h, as was peritoneal neutr

13 The reduced number of lung effector cells in coinfected animals was associated with increased death,

14 the overall host response in SIV-P. fragile-coinfected animals was shifted toward immune activation

15 Treatment of coinfected animals with an antihelminthic improved Mtb-s

16 hat this reduction contributes to disease in coinfected animals.

17 icular stomatitis virus (VSV) as a model, we coinfected BHK cells with VSV DIPs and recombinant helpe

18 Hosts are typically coinfected by multiple parasite species, resulting in po

19 Mammals are coinfected by multiple pathogens that interact through u

20 Most samples were coinfected by multiple viruses, and the majority of iden

21 including human immunodeficiency virus (HIV)-coinfected cases) and rifampicin-resistant tuberculosis.

22 at this process is highly efficient within a coinfected cell and, given synchronous coinfection at mo

23 indirect cell-cell interactions prevent most coinfected cells from being completely suppressed by DIP

24 ent, and exchange of genetic segments inside coinfected cells occurs frequently within types but neve

25 porter expression acquired from thousands of coinfected cells reveal how interference acts at multipl

26 ssembly of heterologous gene segments within coinfected cells, and the fitness associated with reasso

27 These expansions were enhanced in CMV-EBV-coinfected children and were independent of varicella-zo

28 ration of critical drug-drug interactions in coinfected children, as these may significantly impact d

29 A-DR7-restricted CD4(+) T cells from the HIV-coinfected cohort that were specific for epitopes of HCM

30 estimates of recurrence in the high-risk and coinfected cohorts were driven by an increase in reinfec

31 Here we show that in coinfected cultures, AAV2 DNA replication takes place al

32 cific CD4(+) T cells had been activated with coinfected DCs compared to Mtb-infected DCs, and this ef

33 ta, and tumor necrosis factor-alpha, whereas coinfected DCs did not.

34 HCV/HIV-coinfected decedents were more likely to have died of li

35 Among coinfected decedents, 53.6% of deaths were attributed to

36 pe 1/4 (P = .0012) and the proportion of HIV-coinfected DUs (P = .0173) influenced the SVR rate.

37 In the coinfected group with the same initial count, this rate

38 e cirrhotic group, and 0.21 (.10-.45) in the coinfected group.

39 enomic variation, we tracked reassortment in coinfected guinea pigs over time and given matched or di

40 o characterize circulating CD4(+) T cells in coinfected HLA-DR7(+) long-term nonprogressor HIV subjec

41 une responses warrant further studies in HIV coinfected humans able to control their TB infection.

42 Our study comprised 7229 HIV/HCV-coinfected individuals (68% male, 90% white).

43 among human immunodeficiency virus (HIV)/HCV-coinfected individuals according to their baseline fibro

44 erates the progression of HCV disease; thus, coinfected individuals are at high priority for HCV trea

45 ency virus (HIV) and hepatitis C virus (HCV)-coinfected individuals have declined over the last decad

46 eased transition from latent to active TB in coinfected individuals have not been well elucidated at

47 reported at monthly visits in 3381 HIV/HSV-2-coinfected individuals in a placebo-controlled trial of

48 IL-18 was significantly elevated in coinfected individuals versus both monoinfections (p<0.0

49 Coinfected individuals warrant aggressive treatment of b

50 ited generalizability, since the majority of coinfected individuals were not eligible to participate.

51 Genomes of isolate pairs from coinfected individuals were sequenced to determine their

52 d host factors that fuel disease severity in coinfected individuals will help guide the design of eff

53 0% for those with HCV infection, 29.5% among coinfected individuals, and 16.1% for those with neither

54 Higher HIV-1 loads are observed in coinfected individuals, and conversely, HIV-1 is associa

55 nterferon-free regimens, particularly in HIV-coinfected individuals, remains unknown.

56 In HIV/HCV-coinfected individuals, the crude incidence of HCC incre

57 rogression of inflammatory illnesses seen in coinfected individuals.

58 is HLA-DR promiscuous and immunoprevalent in coinfected individuals.

59 FN-alpha/riba in HIV/hepatitis C virus (HCV)-coinfected individuals.

60 y accelerate LTL shortening, particularly in coinfected individuals.

61 ts in a multicohort collaboration of HIV/HCV-coinfected individuals.

62 its use in human immunodeficiency virus/HCV coinfected kidney transplant patients.

63 e treated 6 human immunodeficiency virus/HCV coinfected kidney transplant recipients with ledipasvir-

64 In contrast, independent of transplant era, coinfected LT recipients had increased risk for death (a

65 year, the limited options for treating those coinfected LT recipients with progressive recurrent HCV

66 pulmonary CD4(+) T cells was observed in all coinfected macaques, a subpopulation of the animals was

67 cted, 169 767 HCV-infected, and 6628 HIV/HCV-coinfected male veterans aged 40-75 years.

68 We evaluated 10 090 HIV/HCV-coinfected males from the Veterans Aging Cohort Study Vi

69 Fourteen white HCV/HIV-coinfected males were enrolled in this study.

70 ents (94%) were human immunodeficiency virus coinfected (median CD4 count 16 cells/microL [interquart

71 We show that some of the coinfected mice have sufficiently altered memory T cell

72 ific CD8 T cells adoptively transferred into coinfected mice recapitulated the spectrum of helminth-i

73 s of the mating type distribution in a-alpha coinfected mice suggested no influence of a-alpha intera

74 y to Salmonella-induced intestinal injury in coinfected mice was found to be associated with diminish

75 d HIV-1 infection and dissemination in HSV-2-coinfected mice.

76 ining lymph nodes was detected only in HSV-2-coinfected mice.

77 2D, reversed the increased pathology seen in coinfected mice.

78 inal HIV-1 infection in almost half of HSV-2-coinfected mice.

79 by ICD-9 codes were used to identify HIV/HBV coinfected (n = 144) and HBV monoinfected (n = 225) pati

80 We coinfected NHBE cells with NAI-susceptible and -resistan

81 sks (RRs) for an unfavorable response in the coinfected, non-HAART and HAART groups were 2.1 (95% con

82 In HIV/HCV genotype 1/4-coinfected null responders, a 24-week regimen combining

83 try for Bcc and P. aeruginosa bacteria on 21 coinfected or singly infected CF lungs obtained at trans

84 Coinfected participants had lower mean z scores for trab

85 143 HIV/HBV-coinfected participants with detectable HBV DNA were ide

86 autotaxin levels in HCV-infected and HCV-HIV-coinfected participants, compared with uninfected partic

87 rticipants and with Mac2BP levels in HCV-HIV-coinfected participants, while in HIV-infected individua

88 e hundred and thirty-three patients (56% HIV coinfected) participated, and 15 unfavorable outcomes we

89 ncy virus (HIV)/hepatitis C virus genotype 1-coinfected patients (HIV/HCV-GT1).

90 ncy virus (HIV)/hepatitis C virus genotype 1-coinfected patients (HIV/HCV-GT1).

91 tial proportion of treatment-experienced HIV-coinfected patients achieved SVR24 with a telaprevir-bas

92 gy in HIV/hepatitis C virus (HCV) genotype 3-coinfected patients achieving rapid virologic response f

93 , all-oral, pan-GT HCV treatment for HIV-HCV coinfected patients across a broad range of ARV regimens

94 this oral regimen in diverse populations of coinfected patients are warranted.

95 itoring could be reduced in monoinfected and coinfected patients by estimating the probability of mai

96 -IRIS patients and non-IRIS controls (HIV-TB-coinfected patients commencing antiretroviral therapy wh

97 ative risk of tuberculosis transmission from coinfected patients compared to HIV-negative patients wi

98 Cirrhotic HIV/HCV-coinfected patients enrolled in the French National Agen

99 However, certain coinfected patients exhibit incomplete viral suppression

100 y with DAA-containing therapy, excluding HIV coinfected patients from clinical trials of DAA-containi

101 Mycobacterium tuberculosis (Mtb) and HIV in coinfected patients has profoundly impacted global morta

102 n well-selected HCV-monoinfected and HIV-HCV-coinfected patients in a real-world setting.

103 r SVR in a representative cohort of Canadian coinfected patients in clinical care.

104 pected to further simplify the management of coinfected patients in the transplant setting.

105 incidence of recent HDV infection in HIV/HBV-coinfected patients increased significantly from 1992-20

106 nalyzed HCV treatment outcomes among 255 HCV coinfected patients initiating DAAs between February 201

107 r (OPrD) +/- RBV in HIV/HCV genotype 1 (GT1)-coinfected patients initiating HCV therapy in clinical p

108 Our data suggest that eradication of HCV in coinfected patients is associated not only with a reduct

109 Timely ART initiation in all coinfected patients is crucial.

110 rly cirrhosis in HIV/hepatitis C virus (HCV)-coinfected patients may be challenging.

111 s carried out in hepatitis C virus (HCV)/HIV-coinfected patients on a RTV-boosted ATV-based (ATVr) an

112 A proportion of HIV/HBV-coinfected patients on long-term lamivudine-containing A

113 HCV GT1/HIV-1 coinfected patients on stable DRV-containing ART achieve

114 icacy and safety of OBV/PTV/r + DSV + RBV in coinfected patients on stable, DRV-containing antiretrov

115 randomized, open-label ALLY-2 study, HIV-HCV-coinfected patients received 8 or 12 weeks of once-daily

116 A total of 233 HIV/HCV-coinfected patients received antiviral therapy for HCV,

117 Among previously untreated HIV-HCV coinfected patients receiving daclatasvir plus sofosbuvi

118 in CD4 T cells from HIV-1/hepatitis C virus-coinfected patients receiving highly active antiretrovir

119 argue for the prescription of HCV therapy in coinfected patients regardless of fibrosis stage.

120 Over a 2-year period, only 36.0% of HIV/HBV coinfected patients seen in HIV practices completed HCC

121 In patients with serial samples, only MRSA-coinfected patients showed time-dependent increases in a

122 , and D-dimer (P = .0444) were also found in coinfected patients than in HIV-positive/CMV-negative su

123 For the 4 studies of HIV/HCV coinfected patients the pooled recurrence rate was 32.02

124 ) was sequentially determined in 375 HIV/HBV-coinfected patients to estimate the HDV incidence betwee

125 t that ART should be administered to HIV/HCV-coinfected patients to lower the risk of end-stage liver

126 We included adult VL-HIV coinfected patients treated for VL and discharged cured

127 V) reactivation has been reported in HBV-HCV-coinfected patients treated with DAAs.

128 ficiency virus (HIV)/hepatitis C virus (HCV)-coinfected patients treated with interferon (IFN) and ri

129 is study, we report on treatment outcomes of coinfected patients up to 18 months following treatment

130 The risk of VL relapse in coinfected patients was high, particularly in those not

131 durability of hepatitis C and B clearance in coinfected patients was investigated in a 5-year follow-

132 SVR following hepatitis C therapy in HIV/HCV-coinfected patients was protective (AHR, 0.11; 95% CI, .

133 SVR rates in HIV/HCV GT1-coinfected patients were high.

134 HBV-coinfected patients were more likely to have significant

135 However, in the modern era, 35% of HBV-coinfected patients were not receiving tenofovir.

136 HIV/HCV-coinfected patients were treated for 12 or 24 weeks with

137 Coinfected patients who initiated ART had a significantl

138 man immunodeficiency virus/hepatitis C virus-coinfected patients who relapsed after receiving 12 week

139 study was conducted in HIV/HCV genotype 1/4-coinfected patients who were null responders to prior pe

140 In 413 HIV/HCV-coinfected patients with a virologic response sustained

141 ficiency virus (HIV)/hepatitis C virus (HCV)-coinfected patients with cirrhosis have long been consid

142 D4 cell counts >300 cells/microL and HIV/HCV-coinfected patients with counts >350 cells/microL.

143 ial count, this rate was lower, but 97.6% of coinfected patients with initial counts >350 cells/micro

144 rtunity to transform the outcomes of HIV/HCV-coinfected patients with liver complications.

145 dence interval]) were observed among HIV/HCV-coinfected patients with nonhazardous drinking (14.2 [5.

146 cirrhosis, HCC, or overall mortality between coinfected patients with undetectable HBV DNA and those

147 Of the coinfected patients, 677 (49.4%) patients had at least o

148 uo results in delayed access to DAAs for HIV coinfected patients, a group with more rapid progression

149 deficiency virus-hepatitis C virus (HIV-HCV)-coinfected patients, a population also concerned with el

150 mpairment in PRO scores was noted in HIV/HCV-coinfected patients, compared with HCV-monoinfected pati

151 In HIV/HBV-coinfected patients, infection with multiple HBV genotyp

152 Among HIV/HCV-coinfected patients, statin initiators had lower risks o

153 d regimens for HBV should be prioritized for coinfected patients.

154 ; (3) human immunodeficiency virus (HIV)/HCV coinfected patients.

155 s by antiretroviral (ARV) regimen in HIV-HCV-coinfected patients.

156 approval, small trials were done in HIV-HCV coinfected patients.

157 ese results suggest caution in transplanting coinfected patients.

158 PAVIH, a French nationwide cohort of HIV-HCV-coinfected patients.

159 ay increase the risk for HBV reactivation in coinfected patients.

160 e in antiretroviral therapy (ART) of HIV/HBV-coinfected patients.

161 d and human immunodeficiency virus (HIV)/HBV-coinfected patients.

162 ered as an option for treatment of VL in HIV coinfected patients.

163 s associated with a lower IR risk in HIV-HCV-coinfected patients.

164 is regimen may lead to high failure rates in coinfected patients.

165 cirrhotic human immunodeficiency virus (HIV)-coinfected patients.

166 ed with advanced hepatic fibrosis in HIV/HCV-coinfected patients.

167 ficiency virus (HIV)/hepatitis C virus (HCV)-coinfected patients.

168 rosis progression in a prospective cohort of coinfected patients.

169 e agents in human immunodeficiency virus/HCV-coinfected patients.

170 us (HCV) genotype 1 (GT1) treatment in HIV-1 coinfected patients.

171 wn in human immunodeficiency virus (HIV)/HCV-coinfected patients.

172 ociated with elevated cellular activation in coinfected patients.

173 buvir for acute genotype 1 or 4 HCV in HIV-1-coinfected patients.

174 /microL in 5.7% of monoinfected and 11.1% of coinfected patients.

175 monoinfected and 96.4% (27 of 28) in HIV-HCV-coinfected patients.

176 high virologic efficacy in cirrhotic HIV/HCV-coinfected patients.

177 za virus reassortants can arise in naturally coinfected patients.

178 Fibrosis progression is common among HIV/HCV coinfected patients; these data suggest that progression

179 Initiation of ART in HIV/HSV-2-coinfected persons is associated with a transient increa

180 ficiency virus (HIV)-hepatitis C virus (HCV)-coinfected persons than HIV-monoinfected persons.

181 plasma HIV-1 viral load (VL) in HIV-1/HSV-2 coinfected persons, and this was proposed to be due to a

182 than by the class of anchor agent in HIV-HCV-coinfected persons.

183 representing approximately 23% of the total coinfected population in care in Canada.

184 ent for age, or longitudinal observations in coinfected populations.

185 als (DAAs) in predominantly minority HIV/HCV coinfected populations.

186 a role in protection against cCMV in HIV/CMV-coinfected populations.

187 milar 5-year and 10-year GS, whereas HIV/HCV coinfected recipients had worse GS (5-year: 64.0% versus

188 ients had similar GS and PS, whereas HIV/HCV coinfected recipients had worse outcomes.

189 HIV/HCV coinfected recipients had worse PS compared with HIV-neg

190 virus (HIV) and HIV/hepatitis C virus (HCV) coinfected recipients in the United States is unknown.

191 lthough allograft loss was higher in HIV/HCV coinfected recipients transplanted at enrolling (HR 2.64

192 nt outcomes were superior to HCV+ or HIV/HCV coinfected recipients.

193 Experimental inoculation of a coinfected sample in cell culture yielded two reassortan

194 f 106 human immunodeficiency virus (HIV)/HBV-coinfected subjects maintained on lamivudine, as well as

195 HIV-suppressed coinfected subjects with controlled HIV viral load exper

196 Trabecular volumetric BMD was lower in coinfected than in HCV- or HIV-monoinfected participants

197 S. pneumoniae serotype (ST) 6A or 8 and then coinfected them with mouse-adapted H1N1 influenza A viru

198 sought to determine its efficiency in a host coinfected through transmission.

199 herapy and antituberculosis therapy in HIV-1-coinfected tuberculosis patients.

200 o-platelet ratio index [APRI]) among HIV-HCV-coinfected users of modern protease inhibitor (PI)- and

201 45.9% of HCV-infected, and 33.8% of HIV/HCV-coinfected veterans had an indication for statin therapy

202 Nine hundred ninety-six HIV/HCV GT1-coinfected veterans initiated therapy: 757 LDV/SOF, 138

203 inical Case Registry to identify HIV/HCV GT1-coinfected veterans initiating 12 weeks of LDV/SOF +/- R

204 of HCV-infected, 49.1% and 58.5% of HIV/HCV-coinfected veterans recommended).

205 .57) followed by HBV- (8.72) and HCV- (6.10) coinfected vs 1.27 in HIV-monoinfected patients.

206 berculosis (65% human immunodeficiency virus coinfected) were intensively sampled to determine rifamp

207 otal of 279 patients (62% of whom were HIV-1 coinfected) were recruited.

208 k of the outbreak, although no patients were coinfected, which indicates that exposure to infectious

209 ptible pneumococci survive Cm treatment when coinfected with a CAT-expressing strain.

210 Thirteen (56%) were coinfected with a simian foamy virus known to be acquire

211 Sclerotinia sclerotiorum isolate 328 was coinfected with a strain of Sclerotinia sclerotiorum end

212 V, present latently in B cells, which may be coinfected with both viruses.

213 Furthermore, mice that were coinfected with C. albicans and nonfermentative gram-neg

214 Although most of these animals were coinfected with equine pegivirus (EPgV), also a flavivir

215 Among HIV-positive patients coinfected with HBV and/or HCV who are initiating ART, b

216 ile only a small number of HCV patients were coinfected with HBV, patients with documented HBV viremi

217 Both HEV-positive cases were coinfected with HBV.

218 Real world data on patients coinfected with HCV and HIV treated with SOF-based regim

219 dy of liver fibrosis progression in patients coinfected with HCV and HIV, using the well-characterize

220 and provided high rates of SVR12 in patients coinfected with HCV and HIV-1.

221 ect has been little investigated in patients coinfected with HCV and human immunodeficiency virus (HI

222 controlled study, patients with HIV who were coinfected with HCV genotype 1, 2, or 3 who received the

223 However, outcomes among HIV+ LT recipients coinfected with HCV remain concerning and motivate futur

224 CV-monoinfected adults died, and 5475 adults coinfected with HCV/HIV died.

225 rginase-1, which was elevated in TB patients coinfected with helminths.

226 munodeficiency virus (HIV)-infected patients coinfected with hepatitis B (HBV) and C (HCV) viruses ar

227 Those with prior malignancies or coinfected with hepatitis B or human immunodeficiency vi

228 l cohort study (eight countries), 37 (6%; 32 coinfected with hepatitis C virus [HCV] and five with he

229 scription opioid oxymorphone, and 92.3% were coinfected with hepatitis C virus.

230 Among patients coinfected with hepatitis C, aRR of mortality at 5 years

231 Lower viral load was observed in patients coinfected with HEV.

232 ents with cirrhosis, patients with cirrhosis coinfected with HIV and HCV frequently present at radiol

233 (HCC) are major causes of death for patients coinfected with HIV and hepatitis B virus (HBV).

234 placebo-controlled trial among 3408 persons coinfected with HIV and herpes simplex virus type 2.

235 RM that are similar to those seen in humans coinfected with HIV and HHV-8.

236 revious investigations suggest that patients coinfected with HIV and tuberculosis are less likely to

237 nd especially among children <5 years of age coinfected with HIV or malaria, or who are compromised b

238 atients were excluded if they were pregnant, coinfected with HIV, or infected with hepatitis B, C, or

239 All five subjects were coinfected with HIV-1 and a closely related strain of HC

240 e-group, open-label study involving patients coinfected with HIV-1 and genotype 1 or 4 HCV receiving

241 of sustained virologic response in patients coinfected with HIV-1 and HCV genotype 1 or 4.

242 Children coinfected with HIV-1 had higher levels of TNF-alpha and

243 reviously treated patients, all of whom were coinfected with HIV-1.

244 5A inhibitor velpatasvir for HCV in patients coinfected with HIV-1.

245 nd specificity with samples from 69 patients coinfected with HIV.

246 study included 60 patients, 36 of whom were coinfected with HIV.

247 Patients coinfected with HIV/HCV without advanced fibrosis are at

248 Patients coinfected with HIV/HCV, naive or without sustained viro

249 Human immature DCs coinfected with HIV/Mtb had decreased expression of huma

250 IV acquisition by hCD4/R5/cT1 mice vaginally coinfected with HSV-2 could be completely prevented in a

251 ge was increased ~4-fold in hCD4/R5/cT1 mice coinfected with HSV-2.

252 considered the ideal treatment for patients coinfected with human immunodeficiency virus (HIV) and h

253 recent HDV superinfection among individuals coinfected with human immunodeficiency virus (HIV) and H

254 In a longitudinal cohort of women coinfected with human immunodeficiency virus (HIV) and h

255 Patients coinfected with human immunodeficiency virus (HIV) and h

256 er fibrosis progresses faster in individuals coinfected with human immunodeficiency virus (HIV) and h

257 There are considerable numbers of patients coinfected with human immunodeficiency virus (HIV) and v

258 was determined longitudinally among 96 women coinfected with human immunodeficiency virus (HIV), herp

259 ffective these drugs will be for individuals coinfected with human immunodeficiency virus (HIV)-HCV.

260 or hepatitis C virus (HCV) excluded patients coinfected with human immunodeficiency virus (HIV).

261 ects of THC on fibrosis progression in women coinfected with human immunodeficiency virus (HIV)/HCV e

262 rosis progression in a large cohort of women coinfected with human immunodeficiency virus (HIV)/HCV.

263 A prospective observational study of 176 men coinfected with human immunodeficiency virus and herpes

264 harmacogenetics of efavirenz in 307 patients coinfected with human immunodeficiency virus and tubercu

265 y and safety of this combination in patients coinfected with human immunodeficiency virus type 1 (HIV

266 ment for hepatitis C virus (HCV) in patients coinfected with human immunodeficiency virus type 1 (HIV

267 epatitis C virus (HCV) infection in patients coinfected with human immunodeficiency virus type 1 (HIV

268 ied into general, cirrhotic, and populations coinfected with human immunodeficiency virus.

269 tuberculosis infection, especially in women coinfected with human immunodeficiency virus; (2) evalua

270 he B cell response to IAV is altered in mice coinfected with IAV and S. pneumoniae and that this resp

271 ue specimens were collected from individuals coinfected with KSHV and HIV.

272 single virions released from cells that were coinfected with M tagged with enhanced green fluorescent

273 ation capacity were compared across children coinfected with MRSA or methicillin-susceptible S. aureu

274 In this study, nonhuman primates were coinfected with Mtb and simian immunodeficiency virus (S

275 vo in tissues free of HSV-2 but endogenously coinfected with other HHVs.

276 t adults and adolescents, including patients coinfected with other sexually transmitted infections (s

277 ctive effect in SIV-infected African monkeys coinfected with pegiviruses, possibly because SIV causes

278 fractions from Nicotiana benthamiana plants coinfected with Q-satRNA and its HV confirmed the associ

279 Of positive NPA, 42.1% were coinfected with respiratory viruses.

280 vels in the bronchoalveolar lavage from mice coinfected with S. aureus and influenza.

281 We found that mice coinfected with S. Typhimurium and H. polygyrus develope

282 ed this hypothesis in Ugandan schoolchildren coinfected with Schistosoma mansoni and hookworm.

283 usly shown that 11 patients became naturally coinfected with seasonal H1N1 (A/H1N1) and pandemic H1N1

284 Patients coinfected with syphilis and human immunodeficiency viru

285 h the human immunodeficiency virus (HIV) are coinfected with the hepatitis C virus (HCV) due to share

286 , Botswana, and Zambia; 28% of patients were coinfected with the human immunodefiency virus.

287 he ongoing outbreak in Sierra Leone, 13 were coinfected with the immunomodulatory pegivirus GB virus

288 In the UTI model, mice coinfected with the two species exhibited higher urine p

289 virological response (SVR) rates in the HIV coinfected with those in the HCV monoinfected treated wi

290 iral genotypes generated over time in a host coinfected with two influenza viruses.

291 fector CD8(+) T cells to mice that were then coinfected with two Plasmodium berghei strains, only one

292 , controlled levels of defective viruses are coinfected with viable viruses that have been engineered

293 ts have not been very promising for patients coinfected with VL and human immunodeficiency virus.

294 Among 575 HIV/HCV-coinfected women followed for a median of 11 (interquart

295 red with healthy reference patients, HIV/HCV-coinfected women had decreased tibial trabecular volumet

296 ural underpinnings for skeletal fragility in coinfected women have not been characterized.

297 Among 686 HIV/HCV-coinfected women, 46.0% reported no alcohol use; 26.8% r

298 In HIV/HCV-coinfected women, hepatic fibrosis accelerates with repr

299 In this large cohort of HIV/HCV-coinfected women, THC was not associated with progressio

300 tter predict fibrosis progression in HIV/HCV-coinfected women.